vs
Side-by-side financial comparison of LivaNova PLC (LIVN) and WYNDHAM HOTELS & RESORTS, INC. (WH). Click either name above to swap in a different company.
LivaNova PLC is the larger business by last-quarter revenue ($360.9M vs $334.0M, roughly 1.1× WYNDHAM HOTELS & RESORTS, INC.). LivaNova PLC runs the higher net margin — 8.6% vs -18.0%, a 26.5% gap on every dollar of revenue. On growth, LivaNova PLC posted the faster year-over-year revenue change (12.1% vs -76.3%). WYNDHAM HOTELS & RESORTS, INC. produced more free cash flow last quarter ($168.0M vs $50.2M). Over the past eight quarters, LivaNova PLC's revenue compounded faster (10.6% CAGR vs -4.6%).
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
Wyndham Hotels & Resorts, Inc., is an American hospitality company based in Parsippany, New Jersey, United States. It describes itself as the largest hotel franchisor in the world, with 9,100 locations.
LIVN vs WH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $360.9M | $334.0M |
| Net Profit | $30.9M | $-60.0M |
| Gross Margin | 65.2% | — |
| Operating Margin | 11.8% | — |
| Net Margin | 8.6% | -18.0% |
| Revenue YoY | 12.1% | -76.3% |
| Net Profit YoY | -44.7% | -170.6% |
| EPS (diluted) | $0.57 | $-0.80 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $334.0M | ||
| Q4 25 | $360.9M | $334.0M | ||
| Q3 25 | $357.8M | $382.0M | ||
| Q2 25 | $352.5M | $397.0M | ||
| Q1 25 | $316.9M | $316.0M | ||
| Q4 24 | $321.8M | $336.0M | ||
| Q3 24 | $318.1M | $396.0M | ||
| Q2 24 | $318.6M | $367.0M |
| Q1 26 | — | $-60.0M | ||
| Q4 25 | $30.9M | $-60.0M | ||
| Q3 25 | $26.8M | $105.0M | ||
| Q2 25 | $27.2M | $87.0M | ||
| Q1 25 | $-327.3M | $61.0M | ||
| Q4 24 | $55.9M | $85.0M | ||
| Q3 24 | $33.0M | $102.0M | ||
| Q2 24 | $16.3M | $86.0M |
| Q1 26 | — | — | ||
| Q4 25 | 65.2% | — | ||
| Q3 25 | 68.4% | — | ||
| Q2 25 | 67.8% | — | ||
| Q1 25 | 69.7% | — | ||
| Q4 24 | 68.2% | — | ||
| Q3 24 | 70.8% | — | ||
| Q2 24 | 68.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | -11.4% | ||
| Q3 25 | 15.1% | 46.6% | ||
| Q2 25 | 15.4% | 37.8% | ||
| Q1 25 | 15.3% | 35.4% | ||
| Q4 24 | 11.5% | 38.4% | ||
| Q3 24 | 11.2% | 43.2% | ||
| Q2 24 | 12.6% | 39.5% |
| Q1 26 | — | -18.0% | ||
| Q4 25 | 8.6% | -18.0% | ||
| Q3 25 | 7.5% | 27.5% | ||
| Q2 25 | 7.7% | 21.9% | ||
| Q1 25 | -103.3% | 19.3% | ||
| Q4 24 | 17.4% | 25.3% | ||
| Q3 24 | 10.4% | 25.8% | ||
| Q2 24 | 5.1% | 23.4% |
| Q1 26 | — | $-0.80 | ||
| Q4 25 | $0.57 | $-0.77 | ||
| Q3 25 | $0.49 | $1.36 | ||
| Q2 25 | $0.50 | $1.13 | ||
| Q1 25 | $-6.01 | $0.78 | ||
| Q4 24 | $1.04 | $1.06 | ||
| Q3 24 | $0.60 | $1.29 | ||
| Q2 24 | $0.30 | $1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $635.6M | $64.0M |
| Total DebtLower is stronger | $376.1M | — |
| Stockholders' EquityBook value | $1.2B | $468.0M |
| Total Assets | $2.6B | $4.2B |
| Debt / EquityLower = less leverage | 0.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $64.0M | ||
| Q4 25 | $635.6M | $64.0M | ||
| Q3 25 | $646.1M | $70.0M | ||
| Q2 25 | $593.6M | $50.0M | ||
| Q1 25 | $738.4M | $48.0M | ||
| Q4 24 | $428.9M | $103.0M | ||
| Q3 24 | $346.4M | $72.0M | ||
| Q2 24 | $329.2M | $70.0M |
| Q1 26 | — | — | ||
| Q4 25 | $376.1M | $2.5B | ||
| Q3 25 | $434.5M | $2.6B | ||
| Q2 25 | $430.6M | $2.5B | ||
| Q1 25 | $628.2M | $2.5B | ||
| Q4 24 | $627.0M | $2.4B | ||
| Q3 24 | $625.5M | $2.4B | ||
| Q2 24 | $624.5M | $2.4B |
| Q1 26 | — | $468.0M | ||
| Q4 25 | $1.2B | $468.0M | ||
| Q3 25 | $1.2B | $583.0M | ||
| Q2 25 | $1.1B | $570.0M | ||
| Q1 25 | $1.0B | $579.0M | ||
| Q4 24 | $1.3B | $650.0M | ||
| Q3 24 | $1.3B | $583.0M | ||
| Q2 24 | $1.2B | $623.0M |
| Q1 26 | — | $4.2B | ||
| Q4 25 | $2.6B | $4.2B | ||
| Q3 25 | $2.6B | $4.3B | ||
| Q2 25 | $2.5B | $4.3B | ||
| Q1 25 | $2.6B | $4.2B | ||
| Q4 24 | $2.5B | $4.2B | ||
| Q3 24 | $2.5B | $4.2B | ||
| Q2 24 | $2.5B | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.31× | 5.37× | ||
| Q3 25 | 0.38× | 4.43× | ||
| Q2 25 | 0.38× | 4.44× | ||
| Q1 25 | 0.61× | 4.29× | ||
| Q4 24 | 0.47× | 3.72× | ||
| Q3 24 | 0.48× | 4.19× | ||
| Q2 24 | 0.50× | 3.83× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.4M | $367.0M |
| Free Cash FlowOCF − Capex | $50.2M | $168.0M |
| FCF MarginFCF / Revenue | 13.9% | 50.3% |
| Capex IntensityCapex / Revenue | 8.9% | — |
| Cash ConversionOCF / Net Profit | 2.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | $173.3M | $437.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $367.0M | ||
| Q4 25 | $82.4M | $152.0M | ||
| Q3 25 | $85.1M | $86.0M | ||
| Q2 25 | $62.9M | $70.0M | ||
| Q1 25 | $24.0M | $59.0M | ||
| Q4 24 | $78.7M | $134.0M | ||
| Q3 24 | $51.0M | $79.0M | ||
| Q2 24 | $43.4M | $1.0M |
| Q1 26 | — | $168.0M | ||
| Q4 25 | $50.2M | $136.0M | ||
| Q3 25 | $62.2M | $75.0M | ||
| Q2 25 | $47.8M | $58.0M | ||
| Q1 25 | $13.2M | $52.0M | ||
| Q4 24 | $68.3M | $109.0M | ||
| Q3 24 | $32.8M | $71.0M | ||
| Q2 24 | $31.2M | $-6.0M |
| Q1 26 | — | 50.3% | ||
| Q4 25 | 13.9% | 40.7% | ||
| Q3 25 | 17.4% | 19.6% | ||
| Q2 25 | 13.6% | 14.6% | ||
| Q1 25 | 4.2% | 16.5% | ||
| Q4 24 | 21.2% | 32.4% | ||
| Q3 24 | 10.3% | 17.9% | ||
| Q2 24 | 9.8% | -1.6% |
| Q1 26 | — | — | ||
| Q4 25 | 8.9% | 4.8% | ||
| Q3 25 | 6.4% | 2.9% | ||
| Q2 25 | 4.3% | 3.0% | ||
| Q1 25 | 3.4% | 2.2% | ||
| Q4 24 | 3.2% | 7.4% | ||
| Q3 24 | 5.7% | 2.0% | ||
| Q2 24 | 3.8% | 1.9% |
| Q1 26 | — | — | ||
| Q4 25 | 2.67× | — | ||
| Q3 25 | 3.18× | 0.82× | ||
| Q2 25 | 2.32× | 0.80× | ||
| Q1 25 | — | 0.97× | ||
| Q4 24 | 1.41× | 1.58× | ||
| Q3 24 | 1.55× | 0.77× | ||
| Q2 24 | 2.65× | 0.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
WH
| Fee-related and other revenues | $334.0M | 100% |
| Management and other fees | $2.0M | 1% |
